Article
A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.
Epilepsia - 1 Jun 2022
Campbell Ciarán, McCormack Mark, Patel Sonn, Stapleton Caragh, Bobbili Dheeraj, Krause Roland, Depondt Chantal, Sills Graeme J, Koeleman Bobby P, Striano Pasquale, Zara Federico, Sander Josemir W, Lerche Holger, Kunz Wolfram S, Stefansson Kari, Stefansson Hreinn, Doherty Colin P, Heinzen Erin L, Scheffer Ingrid E, Goldstein David B, O'Brien Terence, Cotter David, Berkovic Samuel F, Sisodiya Sanjay M, Delanty Norman, Cavalleri Gianpiero L
Abstract excerpt
OBJECTIVE: Levetiracetam (LEV) is an effective antiseizure medicine, but 10%-20% of people treated with LEV report psychiatric side-effects, and up to 1% may have psychotic episodes. Pharmacogenomic predictors of these adverse drug reactions (ADRs) have yet to be identified. We sought to determine the contribution of both common and rare genetic variation to psychiatric and behavioral ADRs associated with LEV....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.